

Press Releases

Warren Wang Appointed Vice President and Managing Director for Boston Scientific in China

Jun 14, 2012

Natick, MA (June 14, 2012) –Warren Wang has been appointed Vice President and Managing Director of Boston Scientific Corporation’s (NYSE:BSX) operations in China. Mr. Wang is responsible for leading the company’s team in China and executing the development strategy in the Chinese market. He is based at the company’s China headquarters in Shanghai and reports to Supratim Bose, Executive Vice President and President of Boston Scientific Asia-Pacific.

“With his passion for workforce development, deep knowledge of the China market, strategic thinking capabilities, and business acumen, Warren is well positioned to lead our team as it strives to achieve accelerated growth and further market expansion in China,” said Supratim Bose, executive vice president and president of Boston Scientific Asia-Pacific.

Mr. Wang recently served as general manager of the Orthopedics group at Johnson & Johnson Medical China. His tenure at Johnson & Johnson spanned more than 10 years and included several leadership positions at both the Ethicon Endo-Surgery and DePuy franchises. During his time at Johnson & Johnson, he spearheaded the launch of the company’s new infection prevention business known as the Advanced Sterilization Products franchise, growing it to become the market leader for low temperature sterilization in China. As a result of his achievements, Mr. Wang moved on to manage the growth and development of Johnson & Johnson’s orthopedics and neurosciences franchise, ultimately achieving significant financial growth by building a culture of teamwork, creating an innovative direct-to-consumer marketing campaign, and forming strategic partnerships with government authorities and medical associations. He was promoted to vice president in January 2006 and became a board member of Johnson & Johnson Medical China. Prior to Johnson & Johnson, Mr. Wang held positions at the China Foreign Trade Development Co. and BP Amoco.

Mr. Wang earned a bachelor's degree in Economics from the University of International Business and Economics, Beijing and a master's degree in business administration in Marketing and Finance from the University of Chicago.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. For more information, please visit:

www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our growth strategy and business plans in China. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our

competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:

Steven Campanini

508-652-5740 (office)

Media Relations

Boston Scientific Corporation

steven.campanini@bsci.com

Sean Findlen

617-520-7268 (office)

Media Relations

Weber Shandwick

sfindlen@webershandwick.com

Sean Wirtjes

508-652-5305 (office)

Investor Relations

Boston Scientific Corporation

investor_relations@bsci.com

SOURCE Boston Scientific Corporation